Livdelzi (seladelpar)
Q2 2026 sales more than doubled to $167 million.
The numbers
What it is
Livdelzi treats primary biliary cholangitis, a chronic liver disease. Gilead reported positive Phase 3 IDEAL results in 2026 that support use in patients with elevated alkaline phosphatase.
Why it matters to the stock. Livdelzi is Gilead's fastest-growing liver product. The IDEAL data could extend its use to patients with elevated alkaline phosphatase.
News
Livdelzi Phase 3 IDEAL trial meets primary endpoint in PBC patients with elevated ALP
Gilead said the Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint, a composite of alkaline phosphatase at or below 1.0 times the upper limit of normal with a 15% or greater drop from baseline at Week 52.
FDA grants accelerated approval to Hepcludex, first US treatment for chronic hepatitis delta
The FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection who have no cirrhosis or compensated cirrhosis.
Gilead Q1 2026 beats: product sales ex-Veklury up 8%, product guidance raised, EPS guidance cut to a loss
Gilead's first-quarter revenue rose 4% to $6.96 billion, and product sales excluding Veklury grew 8% to $6.8 billion.